Karuna Therapeutics (KRTX) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free KRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 26, 2024 | investing.comS&P 500 Q1 earnings estimated growth improves; stocks up for weekApril 25, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planApril 22, 2024 | bizjournals.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 9, 2024 | msn.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersApril 4, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Purchases 3,392 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)China Universal Asset Management Co. Ltd. grew its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 349.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,363 shares of the company's stock after acquiring an additional 3,392 shApril 4, 2024 | marketbeat.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Given Average Rating of "Hold" by AnalystsKaruna Therapeutics, Inc. (NASDAQ:KRTX - Get Free Report) has been assigned an average recommendation of "Hold" from the sixteen ratings firms that are covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a hold recommendation and six have issued a buy recommenMarch 24, 2024 | marketbeat.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Stock Position Raised by SG Americas Securities LLCSG Americas Securities LLC raised its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 2,482.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,193 shares of the comMarch 21, 2024 | marketbeat.comDeutsche Bank AG Buys 7,282 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)Deutsche Bank AG raised its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 16.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,584 shares of the company's stock after acquiring aMarch 18, 2024 | marketbeat.comKaruna Therapeutics (NASDAQ:KRTX) Given Neutral Rating at HC WainwrightHC Wainwright restated a "neutral" rating and issued a $330.00 price target on shares of Karuna Therapeutics in a research report on Thursday.March 18, 2024 | marketbeat.comKaruna Therapeutics (NASDAQ:KRTX) Sets New 1-Year High at $329.99Karuna Therapeutics (NASDAQ:KRTX) Reaches New 12-Month High at $329.99March 18, 2024 | marketbeat.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Sees Significant Decrease in Short InterestKaruna Therapeutics, Inc. (NASDAQ:KRTX - Get Free Report) was the target of a large decline in short interest in February. As of February 29th, there was short interest totalling 1,970,000 shares, a decline of 6.6% from the February 14th total of 2,110,000 shares. Based on an average daily volume of 858,500 shares, the days-to-cover ratio is presently 2.3 days.March 18, 2024 | marketbeat.comTrading was temporarily halted for "KRTX" at 07:03 PM with a stated reason of "News pending."March 18, 2024 | marketbeat.comQ1 2024 EPS Estimates for Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reduced by Zacks ResearchKaruna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) - Zacks Research decreased their Q1 2024 earnings estimates for shares of Karuna Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Zacks Research analyst R. Department now expects that the company willMarch 16, 2024 | marketbeat.comHudson Bay Capital Management LP Takes Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Hudson Bay Capital Management LP acquired a new position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 20,000 shares of the company's stock, valued at approximatelyMarch 15, 2024 | marketbeat.comCatalyst Private Wealth LLC Grows Stock Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Catalyst Private Wealth LLC lifted its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 256.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,855 shares of the company's stoMarch 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | marketbeat.comZacks Research Weighs in on Karuna Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:KRTX)Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) - Stock analysts at Zacks Research issued their FY2026 EPS estimates for shares of Karuna Therapeutics in a report released on Wednesday, March 13th. Zacks Research analyst R. Department anticipates that the company will earn ($4.32) per shareMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)March 12, 2024 | marketbeat.comKaruna Therapeutics (NASDAQ:KRTX) Hits New 1-Year High at $321.80Karuna Therapeutics (NASDAQ:KRTX) Reaches New 52-Week High at $321.80March 12, 2024 | insidertrades.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Insider Sells $1,591,700.00 in StockMarch 11, 2024 | marketbeat.comEnvestnet Asset Management Inc. Has $3.41 Million Stock Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Envestnet Asset Management Inc. increased its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 157.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,18March 9, 2024 | marketbeat.comNorthern Trust Corp Raises Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Northern Trust Corp grew its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 9.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,561 shares of the company's stock after buying an addiMarch 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionMarch 2, 2024 | marketbeat.comHsbc Holdings PLC Makes New $2.03 Million Investment in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Hsbc Holdings PLC acquired a new position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,000 shares of the company's stock, valued at approximately $2,029,000. Several other hedgeFebruary 27, 2024 | marketbeat.comAvidity Partners Management LP Sells 155,500 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)Avidity Partners Management LP cut its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 35.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 286,700 shares of the company's stock after selFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbFebruary 26, 2024 | marketbeat.comInvesco Ltd. Cuts Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Invesco Ltd. reduced its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 7.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 365,134 shares of the company's stock after selling 30,423 shares during the period. Invesco Ltd. owned about 0.97%February 25, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 25.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,690 shares of the company's stoFebruary 23, 2024 | marketbeat.comKaruna Therapeutics (NASDAQ:KRTX) Releases Earnings Results, Misses Estimates By $0.36 EPSKaruna Therapeutics (NASDAQ:KRTX - Get Free Report) announced its earnings results on Thursday. The company reported ($3.01) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by ($0.36). The company's revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the prior year, the company posted ($2.22) earnings per share.February 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 23, 2024 | marketbeat.comAigen Investment Management LP Acquires Shares of 2,275 Karuna Therapeutics, Inc. (NASDAQ:KRTX)Aigen Investment Management LP acquired a new stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,275 shares of theFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 21, 2024 | marketbeat.comDeutsche Bank AG Increases Stock Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Deutsche Bank AG raised its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 16.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,584 shares of the company's stock afteFebruary 20, 2024 | marketbeat.comMutual of America Capital Management LLC Has $1.29 Million Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Mutual of America Capital Management LLC cut its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 52.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,646 shares of the company's stock after selling 8,535 shares duriFebruary 19, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 32,548 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)Charles Schwab Investment Management Inc. increased its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 17.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investorFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 18, 2024 | marketbeat.comFmr LLC Acquires 33,579 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)Fmr LLC grew its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,650,167 shares of the company's stock after acquiring an additiFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 260.000 putFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 330.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 280.000 putFebruary 16, 2024 | marketbeat.comShort Interest in Karuna Therapeutics, Inc. (NASDAQ:KRTX) Increases By 15.8%Karuna Therapeutics, Inc. (NASDAQ:KRTX - Get Free Report) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,690,000 shares, an increase of 15.8% from the January 15th total of 1,460,000 shares. Based on an average daily volume of 820,100 shares, the short-interest ratio is presently 2.1 days.February 16, 2024 | marketbeat.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. decreased its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 42.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,560 shares of the company's stock after selling 2,645February 15, 2024 | marketbeat.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Shares Acquired by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ lifted its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 36.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,899 shares of the company's stock afterFebruary 14, 2024 | marketbeat.comAtika Capital Management LLC Has $7.36 Million Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)Atika Capital Management LLC reduced its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX - Free Report) by 33.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,500 shares of the company's stock after selFebruary 14, 2024 | businesswire.comKARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX Get Karuna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. KRTX Media Mentions By Week KRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRTX News Sentiment▼0.000.43▲Average Medical News Sentiment KRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRTX Articles This Week▼04▲KRTX Articles Average Week Get Karuna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRPT News RDY News UTHR News VTRS News CTLT News BGNE News TEVA News BMRN News ROIV News VKTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
